In Brief: Medical Developments International, Ventracor, Anadis, Ozgen, GlaxoSmithKline

Chris Weaver has resigned as Medical Developments Internationa (ASX:MVP) managing director and CEO to take up an executive management position with a bank. Current CFO Jeremy Payling will act as interim CEO while the company searches for a new CEO. Payling has also been appointed to the newly created position of chief operating officer. Former AusBiotech head Tony Coulepis has been appointed as a director.

Jane Wilder, former company secretary and corporate solicitor for Tempo Services, will replace Bernadette Kerrigan as Ventracor's (ASX:VCR) company secretary and legal counsel.

Anadi (ASX:ANX) has appointed part-time consultant to the company, Arie Nudel, as a director.

Perth-based GM mouse supplier Ozgene has entered into a license agreement with French company Cellectis to use its patent for creating, developing and selling mice relating to mouse knock-ins.

GlaxoSmithKline's anti-thrombotic drug Arixtra has been approved by the European Commission for use in surgical patients at high risk of life-threatening venous blood clots. This follows US FDA approval of the same indication in May. Arixtra is a synthetic form of the natural anti-clotting agent heparin, and Brisbane biopharma Alchemia (ASX:ACL) has an identical, generic molecule ready for launch when GSK's five-year market exclusivity expires next year.